Sodium allantoin phosphate is a bone metabolism regulator, the main component of which is aminodiphosphate. It is characterized by a strong affinity for hydroxyapatite in bone, so it can rapidly enter the bone matrix and inhibit osteoclast activity, thus inhibiting the effect of bone resorption. The main treatment is osteoporosis in postmenopausal women. After oral administration, the drug is absorbed in the small intestine and about half of it enters the bone, while the remaining drug is excreted in its original form via the kidneys. In men with osteoporosis, the effect is not certain and should be used with caution. It should also be used with caution in children and adolescents. The drug has two major contraindications, the first being patients with esophageal dysmotility where the drug does not reach the small intestine rapidly. The second is in patients with renal insufficiency, and these two contraindications should be noted.